These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32483205)

  • 1. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction.
    Mandviwala TM; Basra SS; Khalid U; Pickett JK; Przybylowicz R; Shah T; Nambi V; Virani SS; Deswal A
    Int J Obes (Lond); 2020 Jul; 44(7):1561-1567. PubMed ID: 32483205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get With The Guidelines-Heart Failure (GWTG-HF) Registry.
    Powell-Wiley TM; Ngwa J; Kebede S; Lu D; Schulte PJ; Bhatt DL; Yancy C; Fonarow GC; Albert MA
    JACC Heart Fail; 2018 Mar; 6(3):233-242. PubMed ID: 29428434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction.
    Caughey MC; Vaduganathan M; Arora S; Qamar A; Mentz RJ; Chang PP; Yancy CW; Russell SD; Shah SJ; Rosamond WD; Pandey A
    J Am Geriatr Soc; 2021 May; 69(5):1309-1318. PubMed ID: 33401338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index and all-cause readmissions following acute heart failure hospitalization.
    Cox ZL; Lai P; Lewis CM; Lindenfeld J
    Int J Obes (Lond); 2020 Jun; 44(6):1227-1235. PubMed ID: 31863028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.
    Ather S; Chan W; Bozkurt B; Aguilar D; Ramasubbu K; Zachariah AA; Wehrens XH; Deswal A
    J Am Coll Cardiol; 2012 Mar; 59(11):998-1005. PubMed ID: 22402071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox.
    Shah R; Gayat E; Januzzi JL; Sato N; Cohen-Solal A; diSomma S; Fairman E; Harjola VP; Ishihara S; Lassus J; Maggioni A; Metra M; Mueller C; Mueller T; Parenica J; Pascual-Figal D; Peacock WF; Spinar J; van Kimmenade R; Mebazaa A;
    J Am Coll Cardiol; 2014 Mar; 63(8):778-85. PubMed ID: 24315906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology.
    Zeng S; Cai X; Zheng Y; Liu X; Ye M
    Front Cardiovasc Med; 2022; 9():966745. PubMed ID: 35990945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "obesity paradox": does it persist among Israeli patients with decompensated heart failure? A subanalysis of the Heart Failure Survey in Israel (HFSIS).
    Schwartzenberg S; Benderly M; Malnick S; George J; Goland S
    J Card Fail; 2012 Jan; 18(1):62-7. PubMed ID: 22196843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underweight Is Associated with Poor Prognosis in Heart Failure with Preserved Ejection Fraction.
    Matsuhiro Y; Nishino M; Ukita K; Kawamura A; Nakamura H; Yasumoto K; Tsuda M; Okamoto N; Tanaka A; Matsunaga-Lee Y; Yano M; Egami Y; Shutta R; Tanouchi J; Yamada T; Yasumura Y; Tamaki S; Hayashi T; Nakagawa A; Nakagawa Y; Sotomi Y; Nakatani D; Hikoso S; Sakata Y;
    Int Heart J; 2021 Sep; 62(5):1042-1051. PubMed ID: 34544985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.
    Padwal R; McAlister FA; McMurray JJ; Cowie MR; Rich M; Pocock S; Swedberg K; Maggioni A; Gamble G; Ariti C; Earle N; Whalley G; Poppe KK; Doughty RN; Bayes-Genis A;
    Int J Obes (Lond); 2014 Aug; 38(8):1110-4. PubMed ID: 24173404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.
    Khalid U; Wruck LM; Quibrera PM; Bozkurt B; Nambi V; Virani SS; Jneid H; Agarwal S; Chang PP; Loehr L; Basra SS; Rosamond W; Ballantyne CM; Deswal A
    Int J Cardiol; 2017 Apr; 233():61-66. PubMed ID: 28185703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis.
    Zhang J; Begley A; Jackson R; Harrison M; Pellicori P; Clark AL; Cleland JGF
    Clin Res Cardiol; 2019 Feb; 108(2):119-132. PubMed ID: 29951802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction.
    Morgen CS; Haase CL; Oral TK; Schnecke V; Varbo A; Borlaug BA
    Mayo Clin Proc; 2023 Oct; 98(10):1458-1468. PubMed ID: 37565948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study.
    Khalid U; Ather S; Bavishi C; Chan W; Loehr LR; Wruck LM; Rosamond WD; Chang PP; Coresh J; Virani SS; Nambi V; Bozkurt B; Ballantyne CM; Deswal A
    J Am Coll Cardiol; 2014 Dec; 64(25):2743-9. PubMed ID: 25541126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
    Lund LH; Benson L; Dahlström U; Edner M; Friberg L
    JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial.
    Dong B; Yao Y; Xue R; Liang W; He J; Wei F; Dong Y; He X; Liu C
    BMC Med; 2022 Nov; 20(1):423. PubMed ID: 36324141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "Obesity Paradox" in Patients With HFpEF With or Without Comorbid Atrial Fibrillation.
    Guo L; Liu X; Yu P; Zhu W
    Front Cardiovasc Med; 2021; 8():743327. PubMed ID: 35087875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.